Novo Nordisk is taking aim at Eli Lilly with a new obesity drug deal. Meanwhile, a survey shows doctors’ perception of the ...

The trial results are critical, as it brings Eli Lilly's pill one step closer to becoming a new, needle-free alternative for ...

With the closing, Organovo receives an upfront payment, with future milestones to be paid as FXR314 hits key regulatory and commercial milestones. Lilly is acquiring all commercial and intellectual ...

Copycat versions of Eli Lilly’s diabetes drug Mounjaro and obesity drug Zepbound were supposed to go away this week. They’re ...

Circular Genomics, originally founded in New Mexico, and who specializes in circular RNA (circRNA) biomarkers for precision ...

Eli Lilly and Company (NYSE ... taking place April 25 - 30 in Chicago. SAN DIEGO, March 25, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO) (“Organovo” or the “Company ...

SAN DIEGO, March 25, 2025 (GLOBE NEWSWIRE ... including lead asset FXR314, to Eli Lilly and Company (NYSE:LLY) (“Lilly”). The transaction was completed on March 25, 2025.

The trial results are among the pharmaceutical industry's most critical and closely watched of the year, as they bring Eli Lilly's drug ... medical director for UC San Diego's Center for Advanced ...